ReviewRecent patents on nanotechnology2025
Hybrid Nanophotonic Graphene Systems: A Transformative Innovation for Transdermal Drug Delivery.
Review in Recent patents on nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transdermal Drug Delivery Systems (TDDSs) offer non-invasive administration and sustained drug release, enhancing patient compliance. However, the skin's natural barrier, particularly the stratum corneum, limits the effectiveness of TDDS for high molecular weight and hydrophilic substances. Innovations in material science, particularly hybrid nanophotonic graphene systems, present promising solutions. Nanophotonics generate localized photothermal effects to create microchannels in the skin, while graphene enhances permeability through its electrical and thermal conductivity. Hybrid nanophotonic systems, such as photonic crystals, plasmonic nanoparticles, metamaterials, quantum dots, nanowires, fiber optic nanosensors, and nanoantennas, offer precise control and real-time monitoring for applications in cancer therapy, chronic pain management, targeted drug delivery, and personalized medicine. This perspective examines the design, effectiveness, biocompatibility, and clinical implications of these hybrid systems, highlighting their potential to expand transdermal drug delivery and revolutionize treatment in personalized medicine. This particular formulation holds patentability, as supported by product patents that highlight the advancements in hybrid nanophotonic graphene systems for transdermal drug delivery.
Indexed as
Identifiers
39313897What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.